CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Precision BioSciences, Inc. - DTIL CFD

    0.3937
    0.13%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.0094
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026207 %
    Charges from full value of position ($-4.98)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026207%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003985 %
    Charges from full value of position ($0.76)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003985%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Precision BioSciences Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 0.3942
    Open* 0.3847
    1-Year Change* -67.36%
    Day's Range* 0.3847 - 0.4027
    52 wk Range 0.28-1.50
    Average Volume (10 days) 858.25K
    Average Volume (3 months) 19.98M
    Market Cap 49.92M
    P/E Ratio -100.00K
    Shares Outstanding 118.94M
    Revenue 52.29M
    EPS -0.69
    Dividend (Yield %) N/A
    Beta 1.49
    Next Earnings Date Mar 7, 2024

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 8, 2023 0.3937 0.0090 2.34% 0.3847 0.4047 0.3847
    Dec 7, 2023 0.3942 -0.0140 -3.43% 0.4082 0.4086 0.3802
    Dec 6, 2023 0.4052 0.0065 1.63% 0.3987 0.4149 0.3838
    Dec 5, 2023 0.4033 0.0183 4.75% 0.3850 0.4107 0.3725
    Dec 4, 2023 0.3838 0.0151 4.10% 0.3687 0.3899 0.3613
    Dec 1, 2023 0.3610 0.0073 2.06% 0.3537 0.3652 0.3487
    Nov 30, 2023 0.3537 -0.0150 -4.07% 0.3687 0.3935 0.3510
    Nov 29, 2023 0.3687 -0.0380 -9.34% 0.4067 0.4107 0.3586
    Nov 28, 2023 0.3907 0.0020 0.51% 0.3887 0.4001 0.3787
    Nov 27, 2023 0.3867 0.0058 1.52% 0.3809 0.4077 0.3809
    Nov 24, 2023 0.3987 -0.0294 -6.87% 0.4281 0.4288 0.3819
    Nov 22, 2023 0.4128 -0.0058 -1.39% 0.4186 0.4312 0.4087
    Nov 21, 2023 0.4184 -0.0103 -2.40% 0.4287 0.4481 0.4106
    Nov 20, 2023 0.4407 0.0019 0.43% 0.4388 0.4602 0.4387
    Nov 17, 2023 0.4287 0.0480 12.61% 0.3807 0.4312 0.3789
    Nov 16, 2023 0.3809 0.0022 0.58% 0.3787 0.4011 0.3592
    Nov 15, 2023 0.3642 0.0190 5.50% 0.3452 0.3686 0.3438
    Nov 14, 2023 0.3485 0.0097 2.86% 0.3388 0.3486 0.3226
    Nov 13, 2023 0.3395 -0.0295 -7.99% 0.3690 0.3690 0.3378
    Nov 10, 2023 0.3724 -0.0159 -4.09% 0.3883 0.3938 0.3677

    Precision BioSciences, Inc. Events

    Time (UTC) Country Event
    Thursday, March 7, 2024

    Time (UTC)

    13:30

    Country

    US

    Event

    Q4 2023 Precision BioSciences Inc Earnings Release
    Q4 2023 Precision BioSciences Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 25.098 115.529 24.285 22.238 10.883
    Revenue 25.098 115.529 24.285 22.238 10.883
    Total Operating Expense 136.902 148.92 134.113 109.442 58.795
    Selling/General/Admin. Expenses, Total 41.525 39.667 36.052 27.026 13.673
    Research & Development 77.345 107.664 90.62 78.23 43.363
    Depreciation / Amortization 6.594 7.574 7.441 4.186 1.759
    Unusual Expense (Income) 11.438 -5.985 0 0
    Operating Income -111.804 -33.391 -109.828 -87.204 -47.912
    Interest Income (Expense), Net Non-Operating 0.273 2.815 0.822 -5.673 1.875
    Other, Net
    Net Income Before Taxes -111.637 -30.602 -109.006 -92.877 -46.037
    Net Income After Taxes -111.637 -30.602 -109.006 -92.877 -46.037
    Net Income Before Extra. Items -111.637 -30.602 -109.006 -92.877 -46.037
    Net Income -111.637 -30.602 -109.006 -92.877 -46.037
    Income Available to Common Excl. Extra. Items -111.637 -30.602 -109.006 -92.877 -46.037
    Income Available to Common Incl. Extra. Items -111.637 -30.602 -109.006 -92.877 -46.037
    Diluted Net Income -111.637 -30.602 -109.006 -92.877 -46.037
    Diluted Weighted Average Shares 87.8985 58.6881 52.0317 41.9912 49.029
    Diluted EPS Excluding Extraordinary Items -1.27007 -0.52143 -2.09499 -2.21182 -0.93897
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -1.13873 -0.62297 -2.09499 -2.21182 -0.93897
    Gain (Loss) on Sale of Assets -0.106 -0.026
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 19.789 8.78 10.598 7.363 3.82
    Revenue 19.789 8.78 10.598 7.363 3.82
    Total Operating Expense 31.776 33.244 42.525 30.293 33.374
    Selling/General/Admin. Expenses, Total 9.83 11.086 10.015 10.334 10.438
    Research & Development 20.311 20.493 19.416 18.302 21.304
    Depreciation / Amortization 1.635 1.665 1.656 1.657 1.632
    Operating Income -11.987 -24.464 -31.927 -22.93 -29.554
    Interest Income (Expense), Net Non-Operating 0.024 -0.589 3.545 -1.016 -1.434
    Net Income Before Taxes -11.891 -25.06 -28.488 -23.946 -31.035
    Net Income After Taxes -11.891 -25.06 -28.488 -23.946 -31.035
    Net Income Before Extra. Items -11.891 -25.06 -28.488 -23.946 -31.035
    Net Income -11.891 -25.06 -28.488 -23.946 -31.035
    Income Available to Common Excl. Extra. Items -11.891 -25.06 -28.488 -23.946 -31.035
    Income Available to Common Incl. Extra. Items -11.891 -25.06 -28.488 -23.946 -31.035
    Diluted Net Income -11.891 -25.06 -28.488 -23.946 -31.035
    Diluted Weighted Average Shares 114.1 111.301 111.211 110.849 67.9547
    Diluted EPS Excluding Extraordinary Items -0.10422 -0.22515 -0.25616 -0.21602 -0.4567
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.10485 -0.22509 -0.15236 -0.21602 -0.45601
    Unusual Expense (Income) 11.438
    Gain (Loss) on Sale of Assets 0.072 -0.007 -0.106 -0.047
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 199.105 161.754 105.564 193.672 115.675
    Cash and Short Term Investments 189.576 143.663 89.798 180.886 103.193
    Cash & Equivalents 189.576 143.663 89.798 180.886 103.193
    Total Receivables, Net 0.72 0.488 10 0.965 1.027
    Prepaid Expenses 7.552 17.434 5.762 9.497 8.913
    Other Current Assets, Total 1.257 0.169 0.004 2.324 2.542
    Total Assets 238.169 211.498 150.158 235.233 138.6
    Property/Plant/Equipment, Total - Net 23.164 29.334 41.5 39.571 21.147
    Property/Plant/Equipment, Total - Gross 54.252 53.248 60.578 50.22 26.631
    Accumulated Depreciation, Total -31.088 -23.914 -19.078 -10.649 -5.484
    Intangibles, Net 1.348 2.048 1.373 1.432 1.466
    Other Long Term Assets, Total 2.57 4.641 1.721 0.558 0.312
    Total Current Liabilities 59.664 35.98 42.829 26.932 14.075
    Accounts Payable 1.225 1.144 0.792 2.037 2.218
    Accrued Expenses 11.502 12.615 10.947 8.409 3.053
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 46.937 22.221 31.09 16.486 8.804
    Total Liabilities 177.736 120.33 105.733 96.919 98.64
    Total Long Term Debt 22.223 2.478 0 0 0
    Other Liabilities, Total 95.849 81.872 62.904 69.987 84.565
    Total Equity 60.433 91.168 44.425 138.314 39.96
    Redeemable Preferred Stock 0 0.005
    Additional Paid-In Capital 489.696 408.795 331.45 316.333 126.094
    Retained Earnings (Accumulated Deficit) -428.312 -316.675 -286.073 -177.067 -85.187
    Treasury Stock - Common -0.952 -0.952 -0.952 -0.952 -0.952
    Total Liabilities & Shareholders’ Equity 238.169 211.498 150.158 235.233 138.6
    Total Common Shares Outstanding 110.964 60.9021 52.6926 51.1552 49.029
    Accounts Receivable - Trade, Net 0.72 0.488 10 0.965 0.523
    Long Term Investments 4.748 6.842
    Note Receivable - Long Term 7.234 6.879
    Long Term Debt 22.223 2.478
    Common Stock 0.001 0.00031
    Other Equity, Total -0.00031
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 145.852 147.864 169.017 199.105 225.365
    Cash and Short Term Investments 122.231 137.794 158.132 189.576 212.051
    Cash & Equivalents 122.231 137.794 158.132 189.576 212.051
    Total Receivables, Net 15.197 0.652 0.694 0.72 0.715
    Accounts Receivable - Trade, Net 3.51 0.652 0.694 0.72 0.715
    Prepaid Expenses 8.075 8.915 8.424 7.552 12.292
    Other Current Assets, Total 0.349 0.503 1.767 1.257 0.307
    Total Assets 164.344 181.697 204.502 238.169 271.733
    Property/Plant/Equipment, Total - Net 9.815 22.97 21.24 23.164 25.08
    Intangibles, Net 0.977 1.552 1.525 1.348 1.969
    Other Long Term Assets, Total 0.234 0.619 2.754 2.57 9.517
    Total Current Liabilities 50.617 56.399 46.859 59.664 61.148
    Accounts Payable 0.531 0.781 0.701 1.225 1.061
    Accrued Expenses 6.79 8.279 6.478 11.502 10.454
    Notes Payable/Short Term Debt 22.365 22.317 0 0 0
    Other Current Liabilities, Total 20.931 25.022 39.68 46.937 49.633
    Total Liabilities 135.281 147.656 164.325 177.736 187.353
    Total Long Term Debt 0 0 22.27 22.223 22.173
    Other Liabilities, Total 84.664 91.257 95.196 95.849 104.032
    Total Equity 29.063 34.041 40.177 60.433 84.38
    Redeemable Preferred Stock
    Additional Paid-In Capital 503.356 500.255 494.5 489.696 485.155
    Retained Earnings (Accumulated Deficit) -473.342 -465.263 -453.372 -428.312 -399.824
    Treasury Stock - Common -0.952 -0.952 -0.952 -0.952 -0.952
    Total Liabilities & Shareholders’ Equity 164.344 181.697 204.502 238.169 271.733
    Total Common Shares Outstanding 115.68 115.071 112.339 110.964 110.935
    Long Term Investments 1.807 1.807 2.638 4.748 3.091
    Common Stock 0.001 0.001 0.001 0.001 0.001
    Other Equity, Total
    Note Receivable - Long Term 5.659 6.885 7.328 7.234 6.711
    Long Term Debt 0 0 22.27 22.223 22.173
    Preferred Stock - Non Redeemable, Net 0
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -111.637 -30.602 -109.006 -92.877 -46.037
    Cash From Operating Activities -45.753 -10.853 -87.386 -71.015 -51.723
    Cash From Operating Activities 7.798 8.981 8.777 5.317 2.354
    Non-Cash Items 33.976 -8.816 14.857 18.902 2.467
    Changes in Working Capital 24.11 19.584 -2.014 -2.357 -10.507
    Cash From Investing Activities -3.319 -5.803 -5.031 -24.666 -15.663
    Capital Expenditures -3.319 -5.803 -5.031 -24.666 -15.678
    Other Investing Cash Flow Items, Total 0 0.015
    Cash From Financing Activities 94.985 70.521 1.329 173.374 107.777
    Total Cash Dividends Paid
    Issuance (Retirement) of Stock, Net 74.737 67.26 0.689 136.446 109.913
    Net Change in Cash 45.913 53.865 -91.088 77.693 40.391
    Financing Cash Flow Items 0.443 0.791 0.64 -2.622 -2.136
    Issuance (Retirement) of Debt, Net 19.805 2.47 0 39.55
    Cash Interest Paid 0.824
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -25.06 -111.637 -83.149 -59.203 -28.168
    Cash From Operating Activities -31.464 -45.753 -23.91 -53.096 -28.872
    Cash From Operating Activities 1.953 7.798 5.838 3.897 1.968
    Non-Cash Items 6.653 33.976 19.739 12.521 5.571
    Changes in Working Capital -15.01 24.11 33.662 -10.311 -8.243
    Cash From Investing Activities -0.721 -3.319 -2.687 -1.597 -0.818
    Capital Expenditures -0.721 -3.319 -2.687 -1.597 -0.818
    Cash From Financing Activities 0.741 94.985 94.985 95.165 2.249
    Financing Cash Flow Items 0.266 0.443 0.443 0.282 0.282
    Issuance (Retirement) of Stock, Net 0.475 74.737 74.732 74.913 1.967
    Net Change in Cash -31.444 45.913 68.388 40.472 -27.441
    Issuance (Retirement) of Debt, Net 19.805 19.81 19.97
    Cash Interest Paid 0.464 0.824 0.422
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Novartis Pharma AG Corporation 10.7825 12407440 12407440 2022-06-15 LOW
    Great Point Partners, LLC Hedge Fund 6.4914 7469736 -630063 2023-06-30 HIGH
    Capital World Investors Investment Advisor 5.8356 6715043 0 2023-06-30 LOW
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.0995 4717368 -22451 2023-06-30 LOW
    Jantz (Derek) Individual Investor 3.5241 4055174 0 2022-08-03
    Smith (J Jefferson) Individual Investor 3.3744 3882950 5175 2023-08-31 LOW
    Acadian Asset Management LLC Investment Advisor/Hedge Fund 2.5252 2905818 0 2023-06-30 MED
    Citadel Advisors LLC Hedge Fund 2.3568 2712027 -125387 2023-06-30 LOW
    Stifel Nicolaus Investment Advisors Investment Advisor 1.7023 1958872 1049771 2023-06-30 LOW
    Renaissance Technologies LLC Hedge Fund 1.4918 1716663 190325 2023-06-30 HIGH
    Cowen Investment Management LLC Investment Advisor/Hedge Fund 1.3935 1603557 -1866263 2023-06-30 HIGH
    JPMorgan Asset Management U.K. Limited Investment Advisor/Hedge Fund 1.3272 1527224 -35955 2023-06-30 LOW
    UBS O'Connor LLC Hedge Fund 1.163 1338295 422459 2023-06-30 HIGH
    OUP Management Co., LLC Venture Capital 0.9767 1123913 0 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 0.9085 1045394 -179030 2023-06-30 LOW
    Jacobs Levy Equity Management, Inc. Investment Advisor/Hedge Fund 0.6785 780696 -6207 2023-06-30 MED
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.6707 771805 -49321 2023-06-30 LOW
    Marshall Wace LLP Investment Advisor/Hedge Fund 0.564 648945 -370541 2023-06-30 HIGH
    J.P. Morgan Securities LLC Research Firm 0.4836 556485 14938 2023-06-30 MED
    GSA Capital Partners LLP Hedge Fund 0.4084 469990 -22985 2023-06-30 HIGH

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Precision BioSciences, Inc. Company profile

    About Precision BioSciences Inc

    Precision BioSciences, Inc is a clinical stage biotechnology company. The Company’s ARCUS platform is designed to deliver therapeutic-grade genome editing. Its ARCUS genome editing technology is for deoxyribonucleic acid (DNA) genome insertion, deletion and repair. Its ARCUS is based on a naturally occurring genome editing enzyme, I-CreI, that evolved in the algae Chlamydomonas reinhardtii to make specific cuts and DNA insertions in cellular DNA. The Company’s pipeline includes Ex vivo Allogeneic CAR T Immunotherapy and In vivo Gene Correction. Its Ex vivo Allogeneic CAR T Immunotherapy pipeline offers programs, including PBCAR0191, PBCAR19B, PBCAR269A and CD19 Combination with Foralumab. Its in-vivo Gene Correction pipeline offers three preclinical programs, including PBGENE-PCSK9, PBGENE-PH1 and PBGENE-HBV. The Company’s subsidiaries include Precision PlantSciences, Inc. and Precision BioSciences UK Limited.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Precision BioSciences Inc revenues increased from $24.3M to $115.5M. Net loss decreased 72% to $30.6M. Revenues reflect Therapeutics segment increase from $21.9M to $111.7M, Food segment increase of 57% to $3.8M. Lower net loss reflects Therapeutics segment income totaling $32M vs. loss of $50M, Food segment loss decrease of 26% to $3.8M.

    Industry: Biotechnology & Medical Research (NEC)

    302 E Pettigrew St Ste A100
    DURHAM
    NORTH CAROLINA 27701-2393
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    71.33 Price
    -0.180% 1D Chg, %
    Long position overnight fee -0.0213%
    Short position overnight fee -0.0006%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    42,261.70 Price
    -3.660% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.63 Price
    -5.750% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    16,065.10 Price
    -0.100% 1D Chg, %
    Long position overnight fee -0.0262%
    Short position overnight fee 0.0040%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading